Jump to content
Retatrutide Chemical

Chemistry, prolonged exposure and the human trial experience.

Reading list

Retatrutide reading list

The early human trial is the starting point here. The larger trials and reviews give its short observation window some company.

Clinical papers

The 2022 phase 1b trial supplied the roughly six-day half-life and the early weight finding in adults with type 2 diabetes. The obesity trial, diabetes trial and liver-fat substudy followed different populations and outcomes over longer periods. The appetite analysis adds participants’ eating-related reports.

For the chemistry, the receptor structures and cell assays describe molecular activity, while the retatrutide pharmacology review connects design and clinical development.

Comparative evidence

The seven-agent review and network comparison of glucagon receptor agonists compare published results across studies. The dual- and triple-agonist meta-analysis considers efficacy alongside gastrointestinal events and discontinuation. The direct tirzepatide comparison is a trial entry.

The kidney-trial design paper, cardiometabolic review and review of weight regain after discontinuation address questions that extend beyond an early weight endpoint. The Clinical Diabetes profile supplies an overview of retatrutide’s investigational development.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss (review). 2024. ↗
  8. Eli Lilly and Company. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176). ClinicalTrials.gov. 2024. ↗
  9. et al. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. ↗
  10. et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide. Nephrol Dial Transplant. 2025. ↗
  11. Abulehia A, et al. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2026. ↗
  12. et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide. Diabetes Obes Metab. 2025. ↗
  13. et al. Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, and the Path Forward. Cureus. 2026. ↗
  14. Chan ZH, et al. Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis. Cardiology in Review. 2026. ↗
  15. Bhat S, et al. Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. World J Cardiol. 2025;17(8):107991. ↗